search
Back to results

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Primary Purpose

Prostate Cancer Patients

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Repaglinide, Bupropion and SHR3680
Sponsored by
Jiangsu HengRui Medicine Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Prostate Cancer Patients

Eligibility Criteria

45 Years - 75 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • 1. 18 ≤ age ≤75, male;
  • ECOG score of physical condition is 0 ~ 1;
  • The expected survival time is at least 3 months;
  • Prostatic adenocarcinoma confirmed by histological or cytological examination, with no indication of neuroendocrine or small-cell characteristics;
  • Fasting blood glucose level is: 3.9~6.1mmol/L;
  • The functional level of organs must meet the following requirements (no blood transfusion or hematopoietic growth factor treatment was received within 2 weeks before routine blood screening) :

    • ANC ≧ 1.5 x 109 / L;
    • PLT ≧ 80 x 109 / L;
    • Hb ≧ 90 g/L;
    • TBIL ≦1.5 x ULN;
    • ALT and AST≦2.5×ULN;
    • BUN and Cr ≦1.5 x ULN;
    • GFR ≧ 60 ml/min / 1.73 m2.
  • According to the researcher's judgment, it can comply with the experimental scheme;
  • Volunteer to participate in this clinical trial, understand the study procedures and have signed informed consent.

Exclusion Criteria:

  • Any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, etc.), except ADT therapy, shall be completed until the washout period of the first drug administration in this study is <4 weeks;
  • Plan to receive any other anti-tumor therapy during the study;
  • As subjects, to participate in other drug clinical trials, the last trial drug administration is less than 4 weeks from the first administration of the drug in this study;
  • The presence of intracerebral tumor lesions according to imaging diagnosis;
  • Have a history of epilepsy, or have diseases that can induce epileptic seizures within 12 months before the first administration of the drug in this study (including a history of transient ischemic attack, cerebral stroke (except cerebral ischemia lesions found by simple imaging examination), and need to be hospitalized with cerebral trauma and consciousness disorder);
  • Active heart disease, including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, and drug-requiring ventricular arrhythmias, within 6 months prior to the first administration of the drug in this study;
  • Inability to swallow, chronic diarrhea and ileus, history of gastrointestinal surgery, or other factors affecting drug use and absorption as determined by the investigator;
  • Patients with active HBV or HCV infection (HBV copy count ≥ 104 copies /mL, HCV copy count ≥ 103 copies /mL) and active syphilis;
  • A history of immunodeficiency (including HIV positive, other acquired or congenital immunodeficiency diseases) or a history of organ transplantation;
  • Patients who were unwilling to use effective contraceptive methods during the whole study treatment period and within 3 months after the last administration;
  • Allergic constitution, including a history of severe drug allergy or drug allergy;
  • Screening for excessive smoking in the first 6 months (≥5 cigarettes/day) or smoking within 48 hours before the first dose, or not interrupting smokers during the main study trial, and screening for drug use in the first 3 months with a history of drug abuse or positive drug abuse screening;
  • has a history of alcoholism or within 6 months prior to screening often drinkers, namely the essence of drinking more than 14 units of alcohol a week (1 = 360 mL of alcohol content of 5% beer or 45 mL of 40% alcohol liquor or 150 mL wine alcohol content of 12%) or within 48 h before taking the medicine for the first time drinking, or D - 1 in the alcohol breath test positive, or the body can't stop alcohol intake during the study period;
  • Use of any vitamin product, health product or herb 14 days prior to the first administration;
  • Ingestion of grapefruit or fruit juice products such as grapefruit, foods or beverages containing caffeine, xanthine or alcohol within 48 hours before taking the study drug;Strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion;
  • Within 2 weeks before the first drug uptake, uptake CYP2C8 and CYP2B6 inhibitors were used, or drugs affecting gastric acid secretion.;
  • abnormal coagulation function at screening stage (INR >1.5 or prothrombin time (PT) > ULN+4 seconds or APTT> 1.5uln), bleeding tendency or thrombolytic therapy;
  • Repaglinide contraindications (insulin-dependent -IDDM, C-peptide-negative diabetic patients, diabetic ketoacidosis with or without coma);
  • Contraindications to bulimia or anorexia (epileptic history, bulimia or anorexia, abstinence from alcohol or sedatives suddenly);
  • Those with a history of fainting needle or blood, have difficulty in blood collection or cannot tolerate vein puncture for blood collection;
  • Concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease, psychosis, etc.) or any other conditions that, in the investigator's judgment, would seriously endanger the patient's safety or affect the patient's completion of the study.

Sites / Locations

  • Hunan Cancer HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SHR3680+ Repaglinide, Bupropion

Arm Description

Experimental: Repaglinide, Bupropion and SHR3680 Repaglinide and Bupropion QD on Day 1 and Day 21, SHR3680 240 mg once daily (QD) from Study Day 6 - 26

Outcomes

Primary Outcome Measures

Peak Plasma Concentration(Cmax)
Summary of Pharmacokinetic parameters Maximum Plasma concentration (Cmax) for Repaglinide and Bupropion
Area under the plasma concentration versus time curve(AUC0-t)
Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to any time before the last quantifiable concentration(AUC0-t)for Repaglinide and Bupropion

Secondary Outcome Measures

Full Information

First Posted
November 22, 2020
Last Updated
December 7, 2020
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04664725
Brief Title
Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
Official Title
A Single-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Repaglinide (CYP2C8 Substrates) and Bupropion (CYP2B6 Substrates) in Prostate Cancer Patients
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2020 (Actual)
Primary Completion Date
January 2021 (Anticipated)
Study Completion Date
May 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer Patients

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SHR3680+ Repaglinide, Bupropion
Arm Type
Experimental
Arm Description
Experimental: Repaglinide, Bupropion and SHR3680 Repaglinide and Bupropion QD on Day 1 and Day 21, SHR3680 240 mg once daily (QD) from Study Day 6 - 26
Intervention Type
Drug
Intervention Name(s)
Repaglinide, Bupropion and SHR3680
Intervention Description
Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680
Primary Outcome Measure Information:
Title
Peak Plasma Concentration(Cmax)
Description
Summary of Pharmacokinetic parameters Maximum Plasma concentration (Cmax) for Repaglinide and Bupropion
Time Frame
Day1 and Day21
Title
Area under the plasma concentration versus time curve(AUC0-t)
Description
Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to any time before the last quantifiable concentration(AUC0-t)for Repaglinide and Bupropion
Time Frame
Day1 and Day21

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. 18 ≤ age ≤75, male; ECOG score of physical condition is 0 ~ 1; The expected survival time is at least 3 months; Prostatic adenocarcinoma confirmed by histological or cytological examination, with no indication of neuroendocrine or small-cell characteristics; Fasting blood glucose level is: 3.9~6.1mmol/L; The functional level of organs must meet the following requirements (no blood transfusion or hematopoietic growth factor treatment was received within 2 weeks before routine blood screening) : ANC ≧ 1.5 x 109 / L; PLT ≧ 80 x 109 / L; Hb ≧ 90 g/L; TBIL ≦1.5 x ULN; ALT and AST≦2.5×ULN; BUN and Cr ≦1.5 x ULN; GFR ≧ 60 ml/min / 1.73 m2. According to the researcher's judgment, it can comply with the experimental scheme; Volunteer to participate in this clinical trial, understand the study procedures and have signed informed consent. Exclusion Criteria: Any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, etc.), except ADT therapy, shall be completed until the washout period of the first drug administration in this study is <4 weeks; Plan to receive any other anti-tumor therapy during the study; As subjects, to participate in other drug clinical trials, the last trial drug administration is less than 4 weeks from the first administration of the drug in this study; The presence of intracerebral tumor lesions according to imaging diagnosis; Have a history of epilepsy, or have diseases that can induce epileptic seizures within 12 months before the first administration of the drug in this study (including a history of transient ischemic attack, cerebral stroke (except cerebral ischemia lesions found by simple imaging examination), and need to be hospitalized with cerebral trauma and consciousness disorder); Active heart disease, including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, and drug-requiring ventricular arrhythmias, within 6 months prior to the first administration of the drug in this study; Inability to swallow, chronic diarrhea and ileus, history of gastrointestinal surgery, or other factors affecting drug use and absorption as determined by the investigator; Patients with active HBV or HCV infection (HBV copy count ≥ 104 copies /mL, HCV copy count ≥ 103 copies /mL) and active syphilis; A history of immunodeficiency (including HIV positive, other acquired or congenital immunodeficiency diseases) or a history of organ transplantation; Patients who were unwilling to use effective contraceptive methods during the whole study treatment period and within 3 months after the last administration; Allergic constitution, including a history of severe drug allergy or drug allergy; Screening for excessive smoking in the first 6 months (≥5 cigarettes/day) or smoking within 48 hours before the first dose, or not interrupting smokers during the main study trial, and screening for drug use in the first 3 months with a history of drug abuse or positive drug abuse screening; has a history of alcoholism or within 6 months prior to screening often drinkers, namely the essence of drinking more than 14 units of alcohol a week (1 = 360 mL of alcohol content of 5% beer or 45 mL of 40% alcohol liquor or 150 mL wine alcohol content of 12%) or within 48 h before taking the medicine for the first time drinking, or D - 1 in the alcohol breath test positive, or the body can't stop alcohol intake during the study period; Use of any vitamin product, health product or herb 14 days prior to the first administration; Ingestion of grapefruit or fruit juice products such as grapefruit, foods or beverages containing caffeine, xanthine or alcohol within 48 hours before taking the study drug;Strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion; Within 2 weeks before the first drug uptake, uptake CYP2C8 and CYP2B6 inhibitors were used, or drugs affecting gastric acid secretion.; abnormal coagulation function at screening stage (INR >1.5 or prothrombin time (PT) > ULN+4 seconds or APTT> 1.5uln), bleeding tendency or thrombolytic therapy; Repaglinide contraindications (insulin-dependent -IDDM, C-peptide-negative diabetic patients, diabetic ketoacidosis with or without coma); Contraindications to bulimia or anorexia (epileptic history, bulimia or anorexia, abstinence from alcohol or sedatives suddenly); Those with a history of fainting needle or blood, have difficulty in blood collection or cannot tolerate vein puncture for blood collection; Concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease, psychosis, etc.) or any other conditions that, in the investigator's judgment, would seriously endanger the patient's safety or affect the patient's completion of the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yuya Wang, Ph.D
Phone
13918749176
Email
wangyuya@hrglobe.cn
First Name & Middle Initial & Last Name or Official Title & Degree
shijuan kuang, Master
Phone
13601827797
Email
kuangshijuan@hrglobe.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Weiqing Han, Ph.D
Organizational Affiliation
Hunan Cancer Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Weiqing Han, Ph.D
Phone
+86-18684699859
Email
md70210@sina.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

We'll reach out to this number within 24 hrs